Parkinson's Disease: Risk Assessment of Persistent Delirium and Its Management
Trial
N/A
Unknown
May 31, 2023
Safety and Efficacy Study of KL002 in the Treatment of Advanced Primary PD
Trial
Early Phase 1
Unknown
May 30, 2023
PERsonalized SPEeCh Therapy for actIVE Conversation
Trial
N/A
Completed
May 29, 2023
Voice Treatment for Parkinson's Disease
Trial
N/A
Completed
May 29, 2023
Neuromodulation of Sleep Architecture by STN-DBS in Parkinsonian Patients
Trial
N/A
Unknown
May 29, 2023
TRANSEURO Open Label Transplant Study in Parkinson's Disease
Trial
N/A
Completed
May 24, 2023
A Clinical Study of Efficacy, Safety, Tolerability and PK of ND0612H in Subjects With Advanced Parkinson's Disease
Trial
Phase 2
Completed
May 24, 2023
The Effect of Cognitive Functions on Upper Extremity Functionality in Parkinson's Patients
Trial
N/A
Completed
May 23, 2023
Body Weight Gain, Parkinson, Subthalamic Stimulation
Trial
Phase 2
Completed
May 23, 2023
Efficacy of Continuous Apomorphine Infusion on Cognitive and Neuropsychological Functions in Parkinson's Disease
Trial
Phase 3
Completed
May 23, 2023
The Relationship Between Neuropsychological Testing and MRI, PET and COBRE - Project 1: AIM 2 (GE-180)
Trial
Phase 2
Terminated
May 23, 2023
Study of the Fecal Microbiome in Patients With Parkinson's Disease
Trial
Phase 1
Completed
May 23, 2023
Transcranial Direct Current Stimulation and Dual Tasks
Trial
N/A
Unknown
May 22, 2023
Effect of Safinamide on Parkinson's Disease Related Chronic Pain
Trial
Phase 4
Completed
May 21, 2023
Pilot Study to Determine if Working Memory Training Aids Cognitive Functioning in Patients With Parkinson's Disease
Trial
N/A
Unknown
May 18, 2023
Cryotherapy Versus Radiofrequency Ablation for Treatment of Para-hisian Accessory Pathways
Trial
N/A
Completed
May 18, 2023
Emotion Study/Substudy: Flexible Brain Study
Trial
N/A
Completed
May 16, 2023
Application of 18F-FDOPA PET and Magnetic Resonance Spectroscopy (MRS) With HCV and PD
Trial
N/A
Unknown
May 16, 2023
A Study to Evaluate the Pharmacokinetics and Safety of LY03003 in Patients With Advanced-stage PD
Trial
Phase 1
Completed
May 15, 2023